<SEC-DOCUMENT>0001104659-20-056506.txt : 20200505
<SEC-HEADER>0001104659-20-056506.hdr.sgml : 20200505
<ACCEPTANCE-DATETIME>20200505071453
ACCESSION NUMBER:		0001104659-20-056506
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200505
DATE AS OF CHANGE:		20200505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		20846822

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2016119-2_8k.htm
<DESCRIPTION>FORM 8K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:incy="http://incyte.com/20200505">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_incy_incyte.com_20200505 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20200504_20200505 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000879169 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityCentralIndexKey">0000879169</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="incy-20200505.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-05-04to2020-05-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-04</xbrli:startDate>
        <xbrli:endDate>2020-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90F_edei--DocumentType_c20200504__20200505_zJLiuLCW3Yu7"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&#160;
<span id="xdx_90C_edei--DocumentPeriodEndDate_c20200504__20200505_z7Z3gvaNqtM8"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 5, 2020</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20200504__20200505_zF5URlQ12i67"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityRegistrantName">INCYTE CORPORATION</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20200504__20200505_zqpHbsq0nB43"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span><br />
(State or Other Jurisdiction of<br /> Incorporation)</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityFileNumber_c20200504__20200505_z4RzHxYwkzKj"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityFileNumber">001-12400</ix:nonNumeric></span></b></span><br />
(Commission File Number)</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20200504__20200505_zyv0y4QBDWK5"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityTaxIdentificationNumber">94-3136539</ix:nonNumeric></span></b></span><br />
(I.R.S. Employer<br /> Identification No.)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 85%; border-collapse: collapse; margin-right: auto">
<tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20200504__20200505_zxaT8WZi8lWc"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityAddressAddressLine1">1801 Augustine Cut-Off</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: top; width: 50%; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20200504__20200505_z3ivEBsNwd33"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityAddressCityOrTown">Wilmington</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20200504__20200505_zLqT60kYVbd5"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityAddressStateOrProvince">DE</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20200504__20200505_zzChlhhs9KQj"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:EntityAddressPostalZipCode">19803</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_905_edei--CityAreaCode_c20200504__20200505_zgEC8rFBJOH7"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:CityAreaCode">302</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20200504__20200505_zRhnO1lz3bBk"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:LocalPhoneNumber">498-6700</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number,<br />
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span id="xdx_907_edei--WrittenCommunications_c20200504__20200505_zcCGmciaOly2" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written communications pursuant to Rule&#160;425 under
the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_901_edei--SolicitingMaterial_c20200504__20200505_zxzaSSFlrdq5" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12 under
the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_908_edei--PreCommencementTenderOffer_c20200504__20200505_zcnoEELHX6Rb" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20200504__20200505_zol3G6Eo0Zql" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240-13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;symbol(s)&#160;</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--Security12bTitle_c20200504__20200505_zTVTkIPVc02h"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:Security12bTitle">Common Stock, $.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20200504__20200505_z9Nq3lzmbbJk"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" name="dei:TradingSymbol">INCY</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--SecurityExchangeName_c20200504__20200505_zTGchu9eLZ2d"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b&#8211;2
of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: right; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company&#160;&#160; <span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20200504__20200505_zkFtH6ZWj5ha"><ix:nonNumeric contextRef="From2020-05-04to2020-05-05" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange
Act.&#160; <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 2.02</b></td><td><b>Results of Operations and Financial Condition.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 5, 2020, Incyte Corporation issued
a press release announcing financial results for its first fiscal quarter ended March 31, 2020. The full text of the press release
is furnished as Exhibit&#160;99.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item &#160;9.01</b></td><td><b>Financial Statements and Exhibits. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="padding-right: 10pt; width: 1in; text-align: right">(d)</td><td style="text-align: justify"><b>Exhibits</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"></td><td style="width: 0.4in; text-align: left"><a href="tm2016119d2_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td><td style="text-align: justify"><a href="tm2016119d2_ex99-1.htm" style="-sec-extract: exhibit">Press release issued by Incyte Corporation dated May
5, 2020.</a></td>
</tr>     <tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"></td><td style="width: 0.4in; text-align: left">104</td><td style="text-align: justify">Cover Page Interactive Data File (embedded within the
Inline XBRL document).</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dated: May 5, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">INCYTE CORPORATION</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 47%"><span style="font-size: 10pt">/s/ Christiana Stamoulis</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Christiana Stamoulis</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Executive Vice President and</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>









</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk3rH/ZNi4pYRYqIr9FuJdhmyyb+HclbGlvEZWFZZr4ZITpiSQtdIsNxlqWwx6oulUPIsEBGc0bvSFbrGPzN8KKtY2Vc8/7AhDyDnhl25enshcZ61xbzGOS415e9cAJyEMsRTDci+OoJmULnaJxWJSiTw46pZo1O8atN2KsnGapeTdUB2WoyMYRd2cpviGQYwZbu6kF8tZCmiQg6zQRiyXSrvzU366iCeYmV77It+t/gAzMoSW8= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2016119d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="tm2016119d2_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Incyte Reports 2020 First Quarter Financial
Results<BR>
and Provides Updates on Key Clinical Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total product and royalty revenues of $569 million (+24% vs Q1</I></FONT><I>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">2019)
for the quarter ended March 31, 2020; Jakafi<SUP>&reg;</SUP> (ruxolitinib) revenues of $459 million in Q1</FONT></I>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>2020
(+22% vs Q1</I></FONT><I>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">2019)</FONT></I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Pemazyre<SUP>TM</SUP> (pemigatinib) approved by FDA as first targeted
treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Data from successful Phase 3 TRuE-AD program for ruxolitinib cream
presented at Revolutionizing Atopic Dermatitis (RAD) conference; NDA on track for end 2020</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Ruxolitinib and baricitinib in clinical trials to treat patients
suffering from COVID-19 </I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Conference Call and Webcast Scheduled Today
at 8:00 a.m. EDT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>WILMINGTON, Del. &ndash; May
5, 2020</B></FONT> &ndash; Incyte (Nasdaq: INCY) today reports 2020 first quarter financial results, and provides a status update
on the Company&rsquo;s development portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our strong first quarter results highlight continued
revenue momentum, led by robust demand across all three indications for Jakafi<SUP>&reg;</SUP> (ruxolitinib),&rdquo; stated Herv&eacute;
Hoppenot, Chief Executive Officer, Incyte. &ldquo;As we navigate this unprecedented and uncertain time, we have implemented numerous
initiatives as we seek to ensure continuity of patient care. We are continuing to execute on our goals, and we were very pleased
to announce the FDA approval of Pemazyre<SUP>TM</SUP> (pemigatinib), the first of three potential product approvals that we expect
to announce in 2020. The FDA review of the capmatinib NDA and tafasitamab BLA are proceeding as expected and, following positive
results from our Phase 3 TRuE-AD development program in atopic dermatitis, we are also on track to submit the NDA for ruxolitinib
cream at the end of 2020, all of which positions us for what I expect to be a transformational year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Commercial, Supply and Clinical &amp; Regulatory Impact</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While it is currently not possible to predict the overall long-term
impact of the COVID-19 pandemic on Incyte&rsquo;s business, to-date, there has been no impact on the commercial side of the business,
and Incyte currently has ample commercial and clinical supply of our medicines to meet the needs of patients receiving Incyte&rsquo;s
approved medicines and those participating in global clinical trials. Incyte&rsquo;s manufacturing processes are proceeding as
usual, with increased manufacturing efforts for ruxolitinib in place to respond to the COVID-19 pandemic and study requests. Incyte
continues to move forward with its global clinical trials, and late-stage programs remain broadly on track, although short-term
effects may continue to emerge. For example, while ongoing monitoring of already-enrolled patients is expected to continue, new
patient recruitment in certain clinical studies may be impacted. The impact on clinical trials may also vary by disease state and
by severity of disease, as well as by geography, as some regions are more adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ruxolitinib and baricitinib as potential therapies for patients
with COVID-19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte has initiated a Phase 3 clinical trial (RUXCOVID) to
evaluate the efficacy and safety of ruxolitinib plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19
associated cytokine storm. The collaborative study is sponsored by Incyte in the United States and by Novartis outside of the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte is also opening a second Phase 3 clinical trial in the
United States to evaluate the efficacy and safety of ruxolitinib plus SoC, compared to SoC therapy alone, in COVID-19 patients
on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized
by rapid onset of widespread inflammation in the lungs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, Incyte has launched an emergency Expanded Access
Program in the United States to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April, Lilly announced it has entered into an agreement with
the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib
as an arm in NIAID's Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a
potential treatment for hospitalized patients diagnosed with COVID-19 in the US, and Lilly is also planning a study expansion to
include Europe and Asia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Portfolio Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>LIMBER &ndash; key highlights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Key LIMBER development programs,
including the once-a-day (QD) formulation of ruxolitinib, and the ongoing and planned ruxolitinib combinations with parsaclisib
(PI3K</FONT>&delta;), PIM, BET and ALK2 are currently on track.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 4pt">Indication and status</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 30%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Once-a-day ruxolitinib <BR> (JAK1/JAK2)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; width: 69%; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis and polycythemia vera: clinical pharmacology studies</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: left">ruxolitinib + parsaclisib <BR> (JAK1/JAK2 + PI3K&delta;)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Refractory myelofibrosis: Phase 3 in preparation</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; color: #4c4b53; text-align: left">ruxolitinib + INCB53914 <BR> (JAK1/JAK2 + PIM)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #4c4b53">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; color: #4c4b53; text-align: left">Refractory myelofibrosis: Phase 2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: left">ruxolitinib + INCB57643<BR> (JAK1/JAK2 + BET)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Refractory myelofibrosis: Phase 2 in preparation</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">ruxolitinib + INCB00928 <BR> (JAK1/JAK2 + ALK2)</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Myelofibrosis: Phase 2 in preparation</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Oncology beyond MPNs &ndash; key highlights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April, the FDA approved Pemazyre, Incyte&rsquo;s selective
fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced
or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Pemazyre was
reviewed under Breakthrough Therapy designation and granted accelerated approval based on overall response rate and duration of
response. The marketing authorization application (MAA) seeking approval for pemigatinib in Europe is under review by the European
Medicines Agency (EMA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delays in data collection and validation, caused by COVID-19
related disruption, mean that data from the FIGHT-201 clinical trial of pemigatinib in patients with bladder cancer are now expected
to be presented at a medical conference in early 2021; all other clinical trials of pemigatinib are currently progressing as expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data from the Phase 3 REACH 2 trial of ruxolitinib versus best
available therapy (BAT) in patients with steroid-refractory acute graft-versus-host disease (GVHD) have been published in <I>The
New England Journal of Medicine </I>and are also expected to be presented at the 46<SUP>th</SUP> annual meeting of the European
Society for Blood and Marrow Transplantation (EBMT) in August 30-September 2, 2020 (postponed from March 22-25, 2020). The Phase
3 REACH 3 trial of ruxolitinib versus BAT in patients with steroid-refractory chronic GVHD has completed recruitment and results
are expected in the second half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The collaboration and license agreement with MorphoSys for the
development and commercialization of tafasitamab became effective in March. In February, the FDA granted Priority Review for tafasitamab
in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), and set
a PDUFA goal date of August 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preparations are ongoing to initiate the Phase 3 POD1UM-304
trial of retifanlimab (formerly INCMGA0012) in combination with platinum-based chemotherapy as a first-line treatment for patients
with non-small cell lung cancer (NSCLC). Incyte no longer plans to pursue the Phase 3 POD1UM-301 trial of retifanlimab in combination
with chemoradiation therapy (CRT) in participants with unresectable, Stage III NSCLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; vertical-align: top; font-size: 10pt; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Indication and status</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: top; width: 30%; text-align: left">ruxolitinib (JAK1/JAK2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; width: 69%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid-refractory chronic GVHD: Phase 3 (REACH3)<SUP>1</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: top; text-align: left">itacitinib (JAK1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">Treatment-na&iuml;ve chronic GVHD: Phase 3 (GRAVITAS-309)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: top; text-align: left">pemigatinib (FGFR1/2/3)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">Cholangiocarcinoma: Phase 2 (FIGHT-202), Phase 3 (FIGHT-302); MAA under review <BR>Bladder cancer: Phase 2 (FIGHT-201, FIGHT-205) <BR>8p11 MPN: Phase 2 (FIGHT-203) <BR>Tumor agnostic: Phase 2 (FIGHT-207)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>tafasitamab (CD19)<SUP>2</SUP></B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">r/r DLBCL: Phase 2 (L-MIND); Phase 3 (B-MIND); BLA under review <BR>1L DLBCL: Phase 1b (First-MIND)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; vertical-align: top; text-align: left">parsaclisib (PI3K&delta;)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left">Follicular lymphoma: Phase 2 (CITADEL-203) <BR>Marginal zone lymphoma: Phase 2 (CITADEL-204) <BR>Mantle cell lymphoma: Phase 2 (CITADEL-205)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>retifanlimab (PD-1)<SUP>3</SUP></B></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">MSI-high endometrial cancer: Phase 2 (POD1UM-101) <BR>Merkel cell carcinoma: Phase 2 (POD1UM-201) <BR>Anal cancer: Phase 2 (POD1UM-202) <BR>NSCLC: Phase 3 (POD1UM-304) in preparation</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1)</TD><TD>Clinical development of ruxolitinib in GVHD conducted in collaboration with Novartis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2)</TD><TD>Development of tafasitamab in collaboration with MorphoSys</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3)</TD><TD>Retifanlimab licensed from MacroGenics</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Inflammation and Autoimmunity (IAI) &ndash; key highlights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April, safety and efficacy data from the two Phase 3 trials
in the TRuE-AD program evaluating ruxolitinib cream in mild-to-moderate atopic dermatitis were presented at the Revolutionizing
Atopic Dermatitis (RAD) virtual symposium. The 44-week long-term safety and efficacy portion of both the TRuE-AD1 and TRuE-AD2
trials are ongoing and the NDA submission is expected before the end of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The two Phase 3 trials in the TRuE-V pivotal program evaluating
ruxolitinib cream in patients with vitiligo are currently proceeding as planned, and results are expected in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-top: Black 1pt solid; vertical-align: top; font-size: 10pt; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 4pt">Indication and status</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; vertical-align: top; width: 30%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">ruxolitinib cream<BR> (JAK1/JAK2)</TD><TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; vertical-align: top; width: 69%; font: 10pt Times New Roman, Times, Serif; text-align: left">Atopic dermatitis: Phase 3 (TRuE-AD1, TRuE-AD2; primary endpoints met) <BR>Vitiligo: Phase 3 (TRuE-V1, TRuE-V2)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: left">INCB54707 <BR> (JAK1)</TD><TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Hidradenitis suppurativa: Phase 2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: left">parsaclisib <BR> (PI3K&delta;)</TD><TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Autoimmune hemolytic anemia: Phase 2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 4pt; text-align: left">INCB00928<BR> (ALK2)</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 4pt">Fibrodysplasia ossificans progressiva: Phase 2 in preparation</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Discovery and early development &ndash; key highlights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on emerging data from the FGFR4 inhibitor program, development
of INCB62079 has been discontinued because of insufficient efficacy in the target patient population. Incyte&rsquo;s portfolio
of other earlier-stage clinical candidates is summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 30%; padding-bottom: 4pt">Modality</TD><TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 69%; padding-bottom: 4pt">Candidates</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Small molecules</TD><TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INCB01158 (ARG)<SUP>1</SUP>, INCB81776 (AXL/MER), epacadostat (IDO1), INCB59872 (LSD1), INCB86550 (PD-L1)&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monoclonal antibodies<SUP>2</SUP></FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN1949 (OX40), INCAGN2390 (TIM-3)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Bispecific antibodies</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCLA-145 (PD-L1xCD137)<SUP>3</SUP></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1)</TD><TD>INCB01158 development in collaboration with Calithera</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2)</TD><TD>Discovery collaboration with Agenus</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3)</TD><TD>MCLA-145 development in collaboration with Merus</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Partnered &ndash; key highlights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March, Incyte and Lilly announced the FDA has granted Breakthrough
Therapy designation for baricitinib for the treatment of alopecia areata, an autoimmune disorder that can cause unpredictable hair
loss on the scalp, face and other areas of the body. In January, Lilly submitted baricitinib for regulatory review in Europe and
Japan as a treatment for patients with moderate-to-severe atopic dermatitis, and has announced plans to submit for approval in
the U.S. in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February, Incyte and Novartis announced that the NDA for
capmatinib, seeking approval in patients with metastatic non-small cell lung cancer (NSCLC) and with a mutation leading to exon
14 skipping as detected by an FDA-approved test, was accepted for Priority Review by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Indication and status</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; width: 30%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>baricitinib (JAK1/JAK2)<SUP>1</SUP></B></FONT></TD><TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-bottom: 4pt; width: 69%; font: 10pt Times New Roman, Times, Serif; text-align: left">Atopic dermatitis: Phase 3 (BREEZE-AD) <BR>Systemic lupus erythematosus: Phase 3 <BR>Severe alopecia areata: Phase 3 (BRAVE-AA1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>capmatinib (MET)<SUP>2</SUP></B></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">NSCLC (with MET exon 14 skipping mutations): NDA (by Novartis) under review</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1)</TD><TD>Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients
with moderate-to-severe rheumatoid arthritis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2)</TD><TD>Worldwide rights to capmatinib licensed to Novartis</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2020 First Quarter Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial measures presented in this press release for the three months ended March 31, 2020 and 2019 have been prepared by the
Company in accordance with U.S. Generally Accepted Accounting Principles (&ldquo;GAAP&rdquo;), unless otherwise identified as a
Non-GAAP financial measure. Management believes that Non-GAAP information is useful for investors, when considered in conjunction
with Incyte&rsquo;s GAAP disclosures. Management uses such information internally and externally for establishing budgets, operating
goals and financial planning purposes. These metrics are also used to manage the Company&rsquo;s business and monitor performance.
The Company adjusts, where appropriate, for expenses in order to reflect the Company&rsquo;s core operations.</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance
of the Company&rsquo;s core operations. The metrics have been adopted to align the Company with disclosures provided by industry
peers.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP
information is not prepared under a comprehensive set of accounting rules</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
should only be used in conjunction with and to supplement Incyte&rsquo;s operating results as reported under GAAP. Non-GAAP measures
may be defined and calculated differently by other companies in our industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Financial Highlights</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Highlights</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands, except per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Total GAAP revenue</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">497,857</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total GAAP operating income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(664,004</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Non-GAAP operating income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(609,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">126,717</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP net income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(720,642</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">102,312</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP net income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(618,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">134,542</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP basic EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP basic EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP diluted EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP diluted EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Revenue Details</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenue Details</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands)</B></FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Jakafi net product revenue</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">459,479</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">375,611</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Iclusig net product revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,638</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Jakavi product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,571</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Olumiant product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,447</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,037</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Product and royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">457,857</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Milestone and contract revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total GAAP revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">497,857</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Product and Royalty Revenues</B></FONT>
Product and royalty revenues for the quarter ended March 31, 2020 increased 24% over the prior year comparative period as a result
of increases in Jakafi and Iclusig net product revenues and higher product royalty revenues from Jakavi and Olumiant. Jakafi net
product revenues for the quarter ended March 31, 2020 increased 22% over the prior year comparative period, primarily driven by
growth in patient demand across all indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Operating Expenses</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Operating Expense Summary</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands)</B></FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP cost of product revenues</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">27,319</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,588</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP cost of product revenues<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,287</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">270,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">301</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP research and development<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,056,574</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">243,123</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP selling, general and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,148</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">123,983</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP selling, general and administrative<SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">97,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,989</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP change in fair value of acquisition-related contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,671</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP change in fair value of acquisition-related contingent consideration<SUP>4</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP collaboration loss sharing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP collaboration loss sharing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Non-GAAP cost of product revenues excludes the
amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals,
Inc. and the cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> Non-GAAP research and development expenses exclude
the cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> Non-GAAP selling, general and administrative expenses
exclude the cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4.</SUP> Non-GAAP change in fair value of acquisition-related
contingent consideration is null.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development expenses</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">GAAP and Non-GAAP research and
development expense for the quarter ended March 31, 2020 increased 301% and 335%, respectively, compared to the same period in
2019, primarily due to upfront consideration of $805 million related to our collaborative agreement with MorphoSys. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling,
general and administrative expenses</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">GAAP and Non-GAAP
selling, general and administrative expenses for the quarter ended March 31, 2020 decreased 10% and 12%, respectively, compared
to the same period in 2019, primarily due to the timing of certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Other Financial Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Operating income (loss)</B></FONT>
GAAP and Non-GAAP operating income (loss) for the quarter ended March 31, 2020 decreased compared to the same period in 2019 primarily
due to upfront consideration related to our collaborative agreement with MorphoSys, partially offset by the growth in product and
royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash,
cash equivalents and marketable securities position</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020 and December 31, 2019, cash, cash equivalents and marketable securities totaled $1.3 billion and $2.1 billion,
respectively. The decrease reflects the upfront payment and stock purchase related to our collaborative agreement with MorphoSys.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2020 Financial Guidance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has reaffirmed its full year 2020 financial guidance,
as detailed below. The R&amp;D expense guidance now includes the expenses related to Incyte&rsquo;s share of tafasitamab development
costs under the MorphoSys collaboration, but excludes $805 million of upfront consideration paid under the MorphoSys collaboration.
The financial guidance also excludes the impact of any potential future strategic transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">All data in millions</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Current</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Previous</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Jakafi net product revenues</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,880 - $1,950 </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Iclusig net product revenues</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100 - $105 </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP Cost of product revenues</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$130 - $135 </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Cost of product revenues<SUP>1</SUP></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$107 - $112 </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP Research and development expenses</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,210 - $1,280 </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Research and development expenses<SUP>2</SUP></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,079 - $1,149 </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP Selling, general and administrative expenses</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$505 - $535 </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Selling, general and administrative expenses<SUP>2</SUP></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$447 - $477 </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP Change in fair value of acquisition-related contingent consideration</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25 - $27 </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif">Unchanged</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Change in fair value of acquisition-related contingent consideration<SUP>3</SUP></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; width: 10%; text-align: left">$0</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 4pt">Unchanged</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Adjusted to exclude the amortization of licensed
intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated
cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> Adjusted to exclude the estimated cost of stock-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> Adjusted to exclude the change in fair value of
estimated future royalties relating to sales of Iclusig in the licensed territory relating to the acquisition of the European business
of ARIAD Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future Non-GAAP financial measures may also exclude impairment
of goodwill or other assets, changes in the fair value of equity investments in our collaboration partners, non-cash interest expense
related to the amortization of the initial discount on our 2020 Senior Notes and the impact on our tax provision of discrete changes
in our valuation allowance position on deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call and Webcast Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte will hold a conference call and webcast this morning
at 8:00 a.m. EDT. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international
callers. When prompted, provide the conference identification number, 13702083.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are unable to participate, a replay of the conference
call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for
international callers is 201-612-7415. To access the replay you will need the conference identification number, 13702083.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The conference call will also
be webcast live and can be accessed at </FONT><U>investor.incyte.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Incyte</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of
proprietary therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">For additional information on
Incyte, please visit </FONT><U>Incyte.com</U> and follow <U>@Incyte</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Jakafi<SUP>&reg;</SUP> (ruxolitinib)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the
U.S. FDA for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jakafi is also indicated for treatment of polycythemia vera
(PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea as well as adults with intermediate or high-risk
myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jakafi is marketed by Incyte in the United States and by Novartis
as Jakavi<SUP>&reg;</SUP> (ruxolitinib) outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi
is a registered trademark of Novartis AG in countries outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About Pemazyre<SUP>TM</SUP></B></FONT><B>&nbsp;(pemigatinib)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a kinase inhibitor indicated for the treatment of
adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor
receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms
1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is marketed by Incyte in the United States. Incyte
has granted Innovent Biologics, Inc. rights to develop and commercialize pemigatinib in hematology and oncology in Mainland China,
Hong Kong, Macau and Taiwan. Incyte has retained all other rights to develop and commercialize pemigatinib outside of the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, Incyte&rsquo;s marketing authorization application
(MAA) seeking the approval of pemigatinib for patients with cholangiocarcinoma in the EU has been validated by the European Medicines
Agency (EMA) and is currently under review for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with
a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of
systemic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a trademark of Incyte Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About Iclusig<SUP>&reg;</SUP></B></FONT><B>&nbsp;(ponatinib)
tablets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iclusig targets not only native BCR-ABL but also its isoforms
that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance
to other approved TKIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the EU, Iclusig is approved for the treatment of adult patients
with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib;
who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or
who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia
(Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not
clinically appropriate; or who have the T315I mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte has an exclusive license from ARIAD Pharmaceuticals,
Inc., since acquired by Takeda Pharmaceutical Company Limited, to develop and commercialize Iclusig in the European Union and 22
other countries, including Switzerland, Norway, Turkey, Israel and Russia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the historical information set forth herein, the
matters set forth in this release contain predictions, estimates and other forward-looking statements, including without limitation
statements regarding: the expected timing for submission of an NDA for ruxolitinib cream for atopic dermatitis; the expected timing
and results of decisions from the FDA on capmatinib and tafasitamab; expectations regarding the number of product approvals and
whether 2020 will be a transformational year for the Company; the potential impacts of the COVID-19 pandemic and measures taken
to address the pandemic on the Company&rsquo;s business, operations and financial results; plans with respect to clinical trials
of ruxolitinib and baricitinib for patients with COVID-19; expectations with respect to the LIMBER program and the timing of the
LIMBER development programs being on track; plans and expectations for the rest of the Company&rsquo;s development portfolio, including
the timing of receipt and announcement of clinical trial results and progress of development programs for pemigatinib, ruxolitinib
for GVHD, retifanlimab, and ruxolitinib cream for vitiligo; expectations of the Company&rsquo;s collaboration partner for the submission
for approval in the U.S. of baricitinib for atopic dermatitis; and the Company&rsquo;s reaffirmed financial guidance for 2020 and
the expectations underlying such guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements are based on the Company&rsquo;s
current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated
developments in and risks related to: further research and development and the results of clinical trials possibly being unsuccessful
or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers
of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company&rsquo;s
clinical trials, supply chain and other third-party providers, sales and marketing efforts, and business, development and discovery
operations; determinations made by the FDA; the Company's dependence on its relationships with and changes in the plans of its
collaboration partners; the efficacy or safety of the Company&rsquo;s products and the products of the Company&rsquo;s collaboration
partners; the acceptance of the Company&rsquo;s products and the products of the Company&rsquo;s collaboration partners in the
marketplace; market competition; unexpected variations in the demand for the Company&rsquo;s products; unexpected price regulation
or limitations on reimbursement or coverage for the Company&rsquo;s products; sales, marketing, manufacturing and distribution
requirements, including the Company&rsquo;s ability to successfully commercialize and build commercial infrastructure for newly
approved products and any additional products that become approved; greater than expected expenses, including expenses relating
to litigation or strategic activities; and other risks detailed from time to time in the Company&rsquo;s reports filed with the
Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019. The Company
disclaims any intent or obligation to update these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Incyte Contacts</U></B></FONT></TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catalina Loveman</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 302 498 6171</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Booth, DPhil</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 302 498 5914</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>cloveman@incyte.com</U></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>mbooth@incyte.com</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 247.5pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCYTE CORPORATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands, except per share amounts)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">GAAP</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 74%; text-align: left">Product revenues, net</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">486,727</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">396,249</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Product royalty revenues</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">81,780</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,608</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Milestone and contract revenues</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">568,507</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">497,857</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Costs and expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Cost of product revenues (including definite-lived intangible amortization)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,319</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,588</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,085,287</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">270,545</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Selling, general and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111,148</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">123,983</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Change in fair value of acquisition-related contingent consideration</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,627</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,671</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Collaboration loss sharing</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,130</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,232,511</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">423,787</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income (loss) from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(664,004</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">74,070</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense), net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,662</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,373</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(602</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(335</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Unrealized gain (loss) on long term investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(48,132</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,989</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income (loss) before provision for income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(704,076</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">104,097</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">16,566</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,785</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(720,642</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">102,312</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(3.33</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.48</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(3.33</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.47</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Shares used in computing net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216,721</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">214,065</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216,721</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">217,061</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCYTE CORPORATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash, cash equivalents and marketable securities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,302,592</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,117,554</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">351,522</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">308,809</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">410,034</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">377,567</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease right-of-use assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,622</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29,058</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,217</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">112,405</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,179</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Long term investments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">180,993</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">133,657</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Other intangible assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">188,444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">193,828</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Goodwill</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,593</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,593</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,752,422</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,426,750</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable, accrued expenses and other liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">488,308</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">500,462</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Finance lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,869</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,582</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible senior notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,524</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Acquisition-related contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">277,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,937,721</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,598,406</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,752,422</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,426,750</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCYTE CORPORATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RECONCILIATION OF GAAP NET INCOME (LOSS) TO SELECTED NON-GAAP ADJUSTED INFORMATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited, in thousands, except per share amounts)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">GAAP Net Income (Loss)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(720,642</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">102,312</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adjustments<SUP>1</SUP>:</I></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (R&amp;D)<SUP>2</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,713</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,422</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (SG&amp;A)<SUP>2</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,575</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,994</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (COGS)<SUP>2</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">225</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash interest expense related to convertible notes<SUP>3</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">223</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">213</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in fair value of equity investments<SUP>4</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,132</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20,989</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of acquired product rights<SUP>5</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,384</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,384</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of contingent consideration<SUP>6</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,627</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,671</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax effect of Non-GAAP adjustments<SUP>7</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,157</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">359</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Non-GAAP Net Income (Loss)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(618,920</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">134,542</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Non-GAAP net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(2.86</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(2.86</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.62</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Shares used in computing Non-GAAP net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216,721</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">214,065</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216,721</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">217,061</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Included within the Milestone and contract revenues
line item in the Condensed Consolidated Statements of Operations (in thousands) for the three months ended March 31, 2020 and 2019
are upfront consideration and milestones of $0 and $40,000, respectively, earned from our collaborative partners. Included within
the Research and development expenses line item in the Condensed Consolidated Statements of Operations (in thousands) for the three
months ended March 31, 2020 are upfront consideration and milestones of $805,532 related to our collaborative partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> As included within the Cost of product revenues
(including definite-lived intangible amortization) line item; the Research and development expenses line item; and the Selling,
general and administrative expenses line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> As included within the Interest expense line item
in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4.</SUP> As included within the Unrealized gain (loss)
on long term investments line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5.</SUP> As included within the Cost of product revenues
(including definite-lived intangible amortization) line item in the Condensed Consolidated Statements of Operations. Acquired product
rights of licensed intellectual property for Iclusig is amortized utilizing a straight-line method over the estimated useful life
of 12.5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6.</SUP> As included within the Change in fair value of
acquisition-related contingent consideration line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7.</SUP> As included within the Provision for income taxes
line item in the Condensed Consolidated Statements of Operations. Income tax effects of Non-GAAP adjustments are calculated using
the applicable statutory tax rate for the jurisdictions in which the charges are incurred, while taking into consideration any
valuation allowances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>incy-20200505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaOIibPtzp5xmekhuWh2bTlaPycvViUa3ygkMFUGcXkH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:incy="http://incyte.com/20200505" elementFormDefault="qualified" targetNamespace="http://incyte.com/20200505">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://incyte.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>incy-20200505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>incy-20200505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://incyte.com/role/Cover" xlink:href="incy-20200505.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://incyte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2016119d2_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2016119d2_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- .(# 2(  A$! Q$!_\0
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MNO#X^G6JX*2GK&4<9##UG0<;\ZIS::LK[I>% H#J"2PP.1N5S&RGGH&#*?\
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M(W&F9 >2")(XSN8(#N9.4^5BWR,_E@@!Y4\K<F[>/R.^*_Q$^.W[=OQ$\8?
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MQ+&8F7<WS$_U>>'#_P 4YH7J=#T@CG!;&EQ;5SU^8J 2!C#$G'%?@+_P5_\
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M;%T,ER[AW%5>%,72Q>)P52A*.,H\/X^K3]K1I.6)K5\7A:$7R*-9N=E^T2L
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M\OI1ASP=2*=3+#<1\24:'"E/BO/,WR3!XW!Y[F><YSA,BHYEBLRS++<SJ8'
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MO$EQ;7D7AA[63F/^";'P(U_]FO\ X)[_ !\_:P^,-WJ.L?M"_M4^!O%WQ?\
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IY83*L/"C0HW=&C"."R^@U"#?NZJ4>D]=-6BBBN<]T**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630685856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2016119-2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="incy-20200505.xsd" xlink:type="simple"/>
    <context id="From2020-05-04to2020-05-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-05-04to2020-05-05">0000879169</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-05-04to2020-05-05">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-05-04to2020-05-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-05-04to2020-05-05">2020-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-05-04to2020-05-05">INCYTE CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-05-04to2020-05-05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-05-04to2020-05-05">001-12400</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-05-04to2020-05-05">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-05-04to2020-05-05">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-05-04to2020-05-05">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-05-04to2020-05-05">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-05-04to2020-05-05">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-05-04to2020-05-05">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-05-04to2020-05-05">498-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-05-04to2020-05-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-05-04to2020-05-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-05-04to2020-05-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-05-04to2020-05-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-05-04to2020-05-05">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-05-04to2020-05-05">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-05-04to2020-05-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-05-04to2020-05-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2016119-2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://incyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2016119-2_8k.htm">tm2016119-2_8k.htm</File>
    <File>incy-20200505.xsd</File>
    <File>incy-20200505_lab.xml</File>
    <File>incy-20200505_pre.xml</File>
    <File>tm2016119d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #:.:50%AQ#>^\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/2L0P$(=?17)O)VW]@Z';B\N>% 07%&\AF=T--DU(1MI]>].X
MVT7T 81<,O/+-]] 6N6%<@&?@_,8R&"\FFP_1*'\BAV(O "(ZH!6QC(EAM3<
MN6 EI6O8@Y?J0^X1:LYOP2))+4G"#"S\0F1=JY50 26Y<,)KM>#]9^@S3"O
M'BT.%*$J*V#=/-$?I[Z%"V"&$08;OPNH%V*N_HG-'6"GY!3-DAK'L1R;G$L[
M5/#V]/B2URW,$$D."M.K: 0=/:[8>?)K\[#>;EA7\YH7_":=+;\3U;5H[M]G
MUQ]^%V'KM-F9?VQ\%NQ:^/4ONB]02P,$%     @ VCFE4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M/I+#Y7?,YIALJ;F;LUUT5^&^F<TKL_HHTEWRL&%&Q&% T!F"3(C$Q)X$*"I
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MTVE5];-6+S:KEE!0^1<E#__FTU=02P,$%     @ VCFE4+JA.8K7 0  ,@8
M  T   !X;"]S='EL97,N>&ULU55;B]4P$/XK(3_ G';9!:4MZ,*"H+*PY\'7
MM)VV@=Q,I\=V?[U)T]O1!_'@@[XT,]],OOERF33K<9+PT@$@&974?4X[1/N.
ML;[J0/'^C;&@?:0Q3G'TKFM9;QWPN@^3E&3IZ?3 %!>:%ID>U)/"GE1FT)C3
M$V5%UAB](W<T CZ5*R 7+G/ZR*4HG9ASN1)RBG :@,I(XPAZ*9#3)"#]:PPG
MT0LJ%QXEM'$!9+%"_)9+^D^!U>N]*Z3<!*8T D5F.2(X_>2=.7D&?PF1Q3Y/
MUBML'9^2])[N$^;!%RF-J\%M91*Z0D4FH0ERG&B[,**Q+ 01C?)&+7AK-)\U
MK#,6P]-6(.5+.,*OS17WV)"8\[$.QT""BM7TJU[,>%S1"?Q'MLA]H+V_B998
M<3'X8?"KT;/_;3 (SPX:,<[^V&SU/3NW5D[OI6BU@KB6WQ9,;BQ89'RM0SKC
MQ*OG"S>E\@ X2B[@4%1'Y+OC]@PCKK=I;&[5G/Z'FO_V/K>@P7%Y%.VO_K^\
MRW^BF"W=<VC1JP;=4%(.0J+0B\9.U#5$>>&%S.F7\/#*JS[9^]33(R_] W[%
M[^?6T/!!XG-8\1S,Z6Y_"B]-\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L#!!0
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M>1,:+[B<6J\YBR'QC.\?1H]BZ<&8A6#O[I5TXH\<P_?,?P!02P,$%     @
MVCFE4/_ )@B]    A0(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<ZV200J#,!  OR)Y0%=MZ:&HIUZ\MOU T-6(FH3LENKOFWI10:$'+PEAP\Q
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M"=MA/7;AWR"I83KOUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%     @
MVCFE4!\CSP/     $P(   L              ( !     %]R96QS+RYR96QS
M4$L! A0#%     @ VCFE4"?HAPZ"    L0   !               ( !Z0
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #:.:50%AQ#>^\    K @
M$0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #:.:50F5R<(Q &  "<)P  $P              @ &W @  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( -HYI5!>KR'6H (  ),+   8
M      "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #:.:50!__:(E$"  #3!0  %               @ '."P  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #:.:50NJ$YBM<!   R!@  #0
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4!08     "@ * ( "  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2016119-2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2016119-2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20200505_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20200505_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20200505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "incy",
   "nsuri": "http://incyte.com/20200505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2016119-2_8k.htm",
      "contextRef": "From2020-05-04to2020-05-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://incyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2016119-2_8k.htm",
      "contextRef": "From2020-05-04to2020-05-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-20-056506-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-056506-xbrl.zip
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M*,G@KDE3N27":K%-1$L2$!$V7P 1A10IK4<B+C>$KT6W]S-GK_ECM2HM6$)
M[9:03LMM4JS2@(CI\@>0HT)0&:,6$O:)T.ZPL'JYGB1<7HO4,3R@68T<0Q<2
M-I Y@YF41/+^S W+T9*AKQE!^2-!E]7G^YHKXI?Y^/T&2Q3)"1KER)W&F-M
MZA([_QX+:-CX*HNA# *G7GOP%UKJ"*1"O+!S*WCFS2N^PLH\)QMPWD5_B"N.
MAII7-/7I@V!JH$F=K"*L?1E>!"(9Z7]EIN92__  L"5R/&ZV&-2&S0U%$*2
MMJ!!<_/+"3Y7!MRNTB2Z2AF&[\JT-([7 S3M:4L!'@0!<6"Z@A8 +(2H4'JD
MX#.F3WS[G$?[.\XB0N0;75G=?O7=M1L8[9:<-Q6IS=2@T(!H>XM?@,-#%JB1
MQX=&'^;_%J!\<5VN5<>BI\4C%J?Q=IMGLF<5]N#[Z)U!CA]0#"B ]IBB(R(@
M  ?8A!Y9%)&H"/V RF#4B/9Z#9<=5CHD\>?]/7D@7,Z 6))=_ED<[JGC*F1
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MJP 7<[ EO:.(T$KI4QEX*LJ)K7DB4!#A_ITVCI''0?+=\_DE]2ZK-]GOWA[
M_-E8:1I?HE)4+F;#DH.4H+3RO@Q?F_: #K=JC0YJU:Z;K<YO.HEKSV4>MCCB
M-@S41#;OHU:SR':1FM_1/_D/[-[V%C>(Z.6YE%/ 71MJ!K; ZQUI'-D]I):R
MN=^1#R*@$O2WB&.['.V$WPF&Q9(PCL@3]$2N;";ZI[)/%= S8VG5&4N[ED%9
MS0_9XDUN[S9[_X0;C_RJ^&:3FTX3=,#4AW&&CD<CF "QXDPR0EBB<H5'*+^+
M!,R%-OK;.<19X1P%PO%3N!:YITR4L;C(:N-E<YK_VC*_J!E:6(<[C,.;J-0;
MU>\=L?2UP(L<=>3:MWDO&<^TG=H0@R4+DH7ZNV-2$6:(.403&9&.J+6]13E#
M8/Q@#NZGS>D&QUV3!,':82*= $I-$[BAR8IS\-W!NAY^?S7^J?!Q'!5JMFEB
MAT'L%_XF2PL\#*X/N!XB>B(NIQHV0TY"M#F&F<W\M4 WI6*^NO01H]+9B$K7
M+<UVP47)FFR;@V57_<ICU=87:/BC\[G+'M/6<2Z[#N\C2L<BK>7$<>TGH4=1
M][,"G>"-B8D'X+B6VH'_:]>5Q88="42L5TU8H5QT#@L4TZE<S4"1_6XH@A:4
MENLOR]-/$,8BS?PU4=%5AK^S.N0CZG!*30*\ZQ(W7O:YUO/GX??!P_/%C[5Y
MMPE.4551%3632R]>4N8%6;7[?<K$_A(2H) /Z_^DL'(1877PL![4G#2IH,LD
M-WI*CW)?CD]N+O)KD]P" A*54D[)JME"/CM7VEPBQWJRE6PG4:WOF/:(N*$%
M1A"@AIWT)0L__$J#]/>5WW,E\?$K)NG! .QQ>ZQ,Q?RRM64\TJ7W1C#T3>M-
M/OW..GNDZRYA+/BXI!91X_5UB#O%FUM:-&^TM>EK#/)$12VF573DW7N,PP-4
M];C2[/56T-M7.XB%S)[R.*%:KRS(S0KO.$YX5?BUZ7;L@14ONBQ]JAVSQD#/
MOCU 6""Z">I$Y8::?;\2LT!8NVAV.K6XZ<A H.E>0_1!+6U!T'/YV"FD'[Y_
MZ^KK<Y_Q^"&8J:U5^S:K(6H<2Z]M".C,6^HLCB*?JX9I&*QT\65]D40<=C#P
M4C&=79&C'VE^.P'Y(HUR7% %ZF 3D2'1/$Z?1'8%JR!AGSY4 W: K4CP]5,<
MVS:X&&^LFK6S*"(6ON;()7BQ#M_7JD7W]/B\^7D=N?XTOD0EF\XLT-E/"]W:
MI0V2OS9L:VD,WS*LIFH^9[O'#VN@>A9GHI(K%97"W@LA_&9K$I."R7_^7<RH
M>_L,^IG$$60B2]*Y&\:=8&BF)T(X!/DC!@Y(W?Z]BI&@QHW4T7MP]A02=\B6
M_7*/*_-X^(I]S[6+: _YY5U]>XN)U0R9F(55T.1OP]<?(ACLC1*5JD&T!R1*
MV-AQ7!O<LB@:=.TAZA+3'HCYBD;!%9^@HG*!>M0$=0+-8HB*XU$ZT46IG-&^
M9W)L$=MCY@@Q2&A8;R3'^R.0W07T,L^1BX!HF:JG>0 (6&V-PK8>9 /V0 P4
ME1,J,F!6WG1A;3;GF<V)WIH#R3W7]/AKN,N:CI3;0-.YN_)2-Y:B('Z\0@;@
M)#"Y=LTW)3-Y:D5AB10M,1?\[ 6.]\:E' 0M*A&>%:2J+-[[:M6SOD9QTQQE
M(LQ2>KA/S5$9W0 G!7?96DK[BTX Q5+LB[RXO]!S1]D5R^L ,! [#1DY4WM&
M8N?;UZU<)N^K]=PVD=@=VE'W4/6TA3+9=!)ZAA4=&6Q,0HT_JOZBJE-K#;H>
M!OIMVZ0:",FZOP)?" [17)# /^-V^]1T]<?\1RKZ/+GKT/()5)"B#W:!BJLY
MK*B9:2V/[(".=3R73OI=_ZCYAZIY,5#S:Y<(YRA.(<KS"&(9=YN]WJ*H6K/L
M6NWR\S^%5O<CU7TQV>M0>X"N:%/@5_/R:DY7,CO=X$S :I;@C_AC"Q]J"]EX
M6Z@SYA'W18NPS>Q9H6:G;Q_-7\@BYHC_0+O($B6WHZUN%THXXAWM8GU',]\&
M;#X+G3$JA\^;E3A^.15,^DD4<2$/<Q:>79IXJ/#4$G!_X^G4+W-.8?D&:7A0
M>LH07CH.&^Z*%M>^P]01EY-"4?F?!&N&_YMF8L9>+)2/MWM?W)!YZ[PSZ]]9
MZ[A8*(-/'!OUN[:YPSZ%M'[XC#<@:7'<:9&@2> D@_; C <&#3M,K'YQE7_)
M:ANC\NN<W()*0N"U1FJF*]4\?FGM?.L\U*^_:>F,L882[BS.1$4LF+:%VMS6
M'G;1_R33:14YV$5/V/0(<L3U&&/9:9LE>OA:Y=L@S\,SSH%=M:5%Q3.\U'C,
MFL_];O=\'37S"$+_.-]OSLKBC/J&$<SB<Y*=,\WP2N3R-J.O[129< GS!\CB
M:$I4.K# -S#3\:.OYN@*NP^$H\O+Z@JRV,2&UR9NP_P*X6!,Q+PXA L.M,2D
M2B*FJUNZB*DA;!HA39;FH=<#&AA$GN&;*9A3MKT%6@H1N8!TC^Y=>\ -$9L[
MHHJ.&=))CUKR=.IT43*=#ROL,P5)_[AZ%NV(CGO[?F$R[$WEX59''&X5.R-3
M87ZF*W>AU/W,]M8\X+@#\1,,(AF>C)_#E'P'24_+3XKG;=*+7I"2XGRC\ZD%
M MW>BDK4GX#_$\W!CDT[EYX/"?&<22Q5'TF\-WLXY9\+MS<_\@;>:#*[A+ 7
M\]CHQ[NJS4^9_?H4I]Y;YA!VP0W$NA<ZMQ5G@.\@)J2/X#LL6R:3'B.R%\PZ
MV/$3K[N@\M"B?\]6"'A[2R S1P+[@ )NX8@LH!<\ADN>*(.!X)*PI8F*,M;D
M:R!$9_&R$1V[.O/W^O2EJ6QV!X]3631=4-C> B>3?(V%A#KUSLJS4H:_J3N?
M4ZE-;.HS=2=T?7<^5YKQVMDE:-D'V3QZHG0%D_ )DX'C/(\69H#3^-5,# $%
M2<#\3>#HI,)KP[/H':!2Z;H$/RA= E8$A&)S@$<LBKD0@UA0\UK,TQ);G[ V
M5&".%'E6TX,7T]Z8FO'":K(J*\W=2IV3/LHDQ:FE[KBO:&@1YIE<'FAH.L0-
M*J+@S8#'H:.KVN!Y14-R,GI]I<TW&M7/G22!M82(\>ED7G"H::&I"W.[XF+)
M"!::ZN1V"82KS!/G9C"X>'$,T(45!L.J@BT+5@&A(5-+@QMP%:P!B7M5/>HR
M#C\92!,]>O*2%?(7(DAL- -E51]U$HG,I^>9IJ0SC'0C*.71E9[G6I09  "+
M(-6@7<I]5I5*275]@6<\O_X?&D_ W&1:G36AB:'(L\)BA\&WH$ L+(D^WFY^
M$Q&]9A/-7S6CD@LF%T:LJB1C(LXH>-DI4=G1/ZVTC02B#B4ZEN<F-GD^TN0^
M:$-47;HAFENP'XJ1_Q(C#DF;6E#5DIZY(\-225&3!N^/9R^*3PJ,=K$&7""^
M"!,5X2</4GBU+<2?Q'4=63+\I42D,3'KC+CM+5:%T?96L!PEQU0&VN:_#>;-
MO(]<:(F?M\_@E_N- <?<D9DVB3_:6E'%6Z)6X&35!N)DY _: 6$"*)*X7G""
M.?8O4.Z0?I?H(G00*2JU1("PO567;W)$XE6.2 ]>"2#J3YOU43,[OU&_%>.U
MEN0VF3^YS2JYS?O*Z[W0BC<(U<\:1YVOK=K&S\F_W[QGEO#I-[/X):M'C[I!
MP#A7>M[>BJL][\85NW3/'"$->Z(^)0O0_HE^@:=+$(.Y0X/(80!/EQC8[(G%
M1P"2QUJ"#@9QB6?!& D.>]RP7?I,]'=.)C:#1+P5!:PJ\EJ47S9%6G*S.+*B
MO>YHR'Q=-E*U#0F.V]($_.+Q82+SZE4ZIAP<01OWMI37G 7X3:8YC_8-4YN)
M-?(RJGGS;-^:[&5?Q'H\*B]%N<J[^MY^_BP@,[?W(ITIED)5PP572K&%1?K>
MMSV3LH_3P(UKW4^(?Z4#"A'T?WB[.=[6QC>/OU&-()%ARE?<BLK3'QZO2W\I
MZ4T5PIORCK>[]*C)+W.P8X57L,[F8-E]U'3D#D 978J;H;],2K:QQ&B6T[-_
M(1NQ]9&4L'A_?F7%=Z@7C^_D5K.\]3GU[G5R/CS]\2U],?AQ],6HI;XT1\/\
MZ4/6_9RZ;="<\[WU_;'NEDZ]<]WHCT;=OS]K9O?,?*K=WIS>WKJYVWK'H>TO
M7*^SQM!\O!D,"^!4OU[76>WX3$MWG]JG7??L^KE1O+C@WS/?M&)J[\@X&9U8
MAIG) SF&=EM0A]WGLV8[I^9)23LZ']6N6*MSHM&_F_9Y_^NEA<^'-^=MVAGD
M"LZMK3:+F#<R%\PZPP[IZ%^/,S?VZ.I[2\]HSA,]^_)]<-OU"@^G17Y;[=,O
M]X7G+RTZ^J?M/CU_S18*M$J^][_M[=7YWSQU?_1\9;=OBH<^2_X74$L#!!0
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MV>.]?UEH7J!!0>! C!=3R4P#;NOE<WUD-;#[.N,>@)=GV_0]T,O&WX;UQ)I
M'N"Q"^'T@-D\PV4']\V+0Z;95D<X MCQA-T QX,>]QRN?:>7@)4@R[#GPUWA
MP_L86R%N:7/'T(*_P;YK(8;U' "_+LQ5JCK6!Z8"WG/S.=?O $,ARQ$[G]_^
MT;HHJ,<L,SRT'J1]'LD1.P<E3\3[4[0U4.[L0>L*L!,@F(^VS@?@)GBL\;%8
M9/RH=\0N+Q[3])@2$7\*SYU@JC@/@M/T9^OJ&@3P\?9& 2UC'K%?+)V[W1,
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MKJ$%QQ' /.TAG($9NGZ[9W@T"1SY&(K*YPA&(7;"*Q#ZP(R1$@J) ?SQTC7
M799C1CGPI2B\(#%;P1SQ16UX.;[6<N'K'@D-K,) <.<HD(@LJQ?0Y:'1WI1@
M9 O,;P\D&LT!7.3W^^AEP0I&,;=?>*]_ J#XR3>!8T#\6F %-"]E(YG^6H2/
M^C^% OML"%/_R.[X$V#U!_&7CV@#'LL*A2#^_^FB]4<2B%)+"2BJAI^U;0=$
M)_KLS$194>'E+LB%#@.XFV+S1U%0$.F?#SJ_CB1B,PWG>,(>!WVXHNGPMJ&!
MG\)[0M+AQL;)J_&;?@WOPF\BP'D'_P?B)-"I#X\IM$'TOQ?: N05GLS-%SYP
M1Z=32Y@.DC5.HMCBQ7EAY,WQD>(,Y.)ED_O^[!HFV ./@9W5? ?0K0=R!28;
M=:!K8$@#M!W87X &4FO:8-I069J 2@J 1< K-4C00NL1N0. P0!J@.8&#2W-
M?(3( (<8%KC 8-7L F(W,F\.FG'X4@@+AL#"QTI0IT7BSUQ ?^';HB?)R'R
M-(=3P0=RA 7Q!^"5D9_C2ET"ST.;U,.9XA-QWCTAY*0ML'-N#!RX#!&)\8P&
M;G1J,(PPP#1\%%G0K@W&KL_1DS3P,7 K&+<GTV[#(,:\KJ-Q@L%*^AV@AD]N
M%UE>U\4GC]OA?,YW?521%*\R++1X+@YFY &BTR'0/1YF@ 'U03_0HH.Y[MLX
M<'O*LN*L7,_7$<.#/+I>-&PPM $<E60$<N"K7KBC!^."=R?/7,(HT."B )#R
M281  "G>0\37=FRNXWH%9A]--]#6?^HRMPN3"G@29@BF&@DWB+ Q03?@@2?
M=9\Q]O&#.$-!JV\BFGNRD3@]&P"C372"%><F4% ?%(3E *8!2D8L8,1 #SPY
M?(L"W/*2SX4P$AC% 6A)H ;=ZP"X#MD/*&@(.="V")A>Z!*;#45@W"W'RPG^
M/',P=0#N=</%E99 '(F8S\&G+D J)P"VP16*!,'HP+IXXY-  O>[ _K"!:<!
MQOQ$Z >YJV<CT-+A,:X LD?CR[1-?3W* =,<(F?4.[R/*X#", QR$)\.45*V
M042@]E#9!=X. O$(8(\R#SNX__:_-#/TP4%4P%_PI;<E4#/ E9K$5B[O",D[
M<271-P$5 YN!<^_H!;M30$^)'3S8Y^"E:.A[.U(BX). O,BKM@6LAPHFE)\1
M"H/>=%U;DR.'R=C?07/"6P!=2U'00/HX8!ERY *] Q*(.LJU'>G@!F0PI,7X
M!I2 SQ\\VJ(E)ABP&_".'(R-VKX7MR/RXGQ.7IUI[@YGZ0;^#[C8I/M!V#54
MV%-675(EGQLE"ZK$9=8?UG:>Q8Y9C5"P0)GUA-;E<FS/*(8F.5#2@>[:TI>G
M& (9(<.1>![TEP=_PYH/+-U!/770O+]X *8#5PS0(XTS=GV'&R:Y]UWNH,YR
M (-*K8@"#[Z?Y0I"+2\83>JCFH<A=TS>DPY=R$>F;SUEFR.:NFY(%]0<A"$5
M4@8F!W^_2TYY8/G@.W;Y@VRXSIJT#Y'/W0V=[4G!P< !.O-,@"- B#!9@ME4
M 99H O&2B#-2IDG:LEBS[Q@ I*X,VM +8B<Z@F4D+06%\4^+(BN,/SF"8D]$
ME7R.8A!A8*!EN9[A4<BHPYH (YPG*6$M"V$*;BFR"VF>779PTVJ";E8(+(;Z
M:?)1A$>_"D0_>,M7#!'9@6*,63M4K#0^A]:7GOW?+FOJO$^:-%J^QVC7\Q'U
MA=2Z\G$O0 *X^1DP7AB7FZHIQ@PM!R0TM+4C&ZL B/N&!^[EWW%4I1O\R;(1
MLHYR5\B;#Q(ARE4)=2" 5BM4@C1B@2SNHA"CA0,8;/J@ZR]]![0EW=]T#9YI
M!OQT=GH7QJJ#/*/-B=5<M:[/+N^C^/]W,1B&JMVTMRW>93L$T[V"62:$+=$=
ME4Q'$6-TFT%W%'@!=SP._@7 "\.&?F#W1NVK$KB+0X>$-CV0PT$H1C:%[5[;
ML(*(O<Q/X([+P>Z[*/<'=ZWR[T%XY!==F!X_ 1UQU[I6V-GEHY2"J]]+,KX=
M.<RA7Y5MX9@C:%;:^:!9:1\T2^"^^1(,@I<&?$#.1]\%&H2_G;!P6[]8_'F1
MK6H<P=3$ DE!8#]@MR<' (>.K[:=C^S/+F"R#R&UALD%KS/J"4M(78BXFQ9P
MXHX)ANYS'=78<'G'N=P4G=C"CB8_S!K?S*$@44Q]KG5/&.C(L!8F7IJ#2UR(
M<2I.SJ&"<VA%.[-!T UWO8<I%DNRE//4/B@5*TJIW%!*U>IA G<E#CI@_/*0
M[^<FPB37W [M8MRT8:XU._BM^;OZ*_Q3.IR64[.0Z+W&"@ETG[)FP:MKQPN\
M.VGFUP- #1VC[=BN(<,3?=L<@.?4%3V#X[OYQZ$/WP<GML=QY<!S"&*&*W/
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M*+V0OI:!:UCD[X*2++CO=6W'^#MX;;]OAK[4P76S>4C)H'1=^&+:!QZF7J)
M!H%C2D;5B5J4+PFDP664WW(KG[N.4CZ:<JOEX/*Z>9CI4-J%,/D MXV9C@4J
M&-^@'0FY0D /0R=J*4SCOBOY8;AIZPB35DTW7,?OR^MZ0 J9?JI')2\D6JTO
M7Q\+I:(ZOC.)>36C]![=80+ITI'J&K*Z0_%*"_>C@N0+RFUM8Z9(K#B&R_0;
M3# 9INW#DX'-06Q*Q9)Z(G,^B?O'LRO&1C0:(:48KW#=L<37;*_RR$J$OL?]
M9?/\*YB<:!GB)ATS/GS,QG*]?(X_<\,DS1/N\1Z<-1\/)]?*]81C&WK!&6(G
MN9,+LM[Q"O*AA:Z->>A!QLK!ES^^7AS*75_*_>K[;? +N[2YQK#6%K>M<::7
MUI.)7/F;[3N6''$H<51\0FGM85YP/#=GG#N0")4:I5M[W2#=FEN6#\_$G*\@
M]6=4MA]LS< ]+E0/9Z9MRU3T:U";P(N/F J,,7HO4"V79]>2/$W_"9/NR\7"
M Y@#T6L#NY5DJ00[Z ,=0&G!H&AM9+%NJ50H!<44AU*9T7KE<^&"E5]=,%B7
MN99% ^4,3,^0^K2CB;OY)E9 CN0L46FSS-P&-G#$D*[!CER0==#E9B=,I\ZT
M*(PEDP2*#HR"0-LRNHW+KFVGW[4?!FYHL_.Y^'8/)1)&>86AC4'6B>7+MX7&
M>[1?*C$#$HY6&M/EV&?1=GSN#(;P([2*=XYA4^[6O;0V-(+A<W&'*;X%) =L
M"@M5MMW#W)9$G($JN^_*TM08.^A&!S !( LL@V5G!0TSQ,Q!#Z8/X.' ^=5A
M%U=GYU>'<G_*%:@5V-W%M\]-*H! 92^WMT.&5[+/"W=#H"VSW<(M-] 982+5
MB,:\N[U0OUT7RL4*E@F'0@@:H\,MT\#5/L"=/8%&!CRBZR_-8E$MD2*86*H^
M;O]9?J\@D8[6%3T[RJ#!ZB:J]BB8J-U&=\['LM0LVRJX/;1F<M%\F$!@*P]N
M'LZOS@_#Q$Q,J\7$7?@&E14E=_1]4!M39JFRY$F.3B<8!DW X;HAYQ@9BO/[
MT% $N:^15HI#6@7S38#S6JT6HT%GFG'FV8 L[_P&9'F_ ;GS&Y"O[J%-#;2\
MN@%9V90-R$J6-B"SOM>X.JU?W["C_<K7HYBO;#@N'XVD@47[E:_S0SIOH:W)
MR9DNV30@H1_!P^O>Q'!SZX <EO(A>5JJ=+0F.@2DK)#6QD>3% 4@KL59)UVN
M62NK3$XFRO\L6/P7P^^9)\]BVK)^N6_^T7IL/@!$/#[<:.4P28=XX(="M^JO
MI5_+&[VTYQ/1X.%VPT$8EBMA<F"XP/+#,GQXPJZ;S=&P)V[PG(W$Y!(>IRI1
MP*]Z2+<T^JJ*&P4)%Y?E%8]^#QLN8?XOK%3"=?75F>UUM;%NYDJY-<E_P-,V
M.@/*Y8V'' [.+[#Q&:K;4JAU98XO6]<(XK!Z<R4E"G/$F.^J<-VZN0!!B*3C
M+/P$6R%,B(9Z-?H(%?4(N?)TU[:IRU@>ST$::3M98(//X&09FF]R)PJ!Q1CB
M'$S?Q>754&]=DWQPD_UM6^+U.RKA'9:'-<GQ(%OB]=7U:;R4LP9627!,#YJ"
M(AP-Q]U=%%2I"<MQ33C23VO]*0DK>X+I9Q\\M JX28]M4.R>D'&^"6L>1 +5
MHAKPK7"^BR#.F 0F@NM+X?5-ZY6G(N:@JRC>%X.7PRCKX9SI$/.UL%XH\K)4
M>&6=O>6.JH;UX73H9)Q&K4_B6Q)CFT) /MK@P3T:/]RV&=W^H%!L6!<[I7';
M-E!NZ-2?7HP2+ Z=DLD3[0-M,7V&/L[I?5R%!EMCT1ZEYMA?!##>-%ID,5S?
M.FW%*WNI]LGW;*/7\RW<8CMH-5N'&Y_ %%1AXNRBZLS1' SOQ8[4K,QUH&U$
M_&J\!6E0%HZ[81.=2%%*P#[KP(R%GJT+F9$SWJ=+MD*;V'@?ZUN:STUK7/IL
M.!YNR;L D&S7\(-. )5*X04;N$4=:!+GC8W^@LU8$)!N?(HJ71G\40HV\D;W
M_\(2/.PB1DW%7$J7BK?\D)L2XYW$,KUK]9C( 2S. '^POO$<]C8?XX-\+I$1
M1C,-GN%KD!M[,FDFUBPNJ&94XMD%;#RY )-TUDC.K=R&>>]MEO652BT^NL5H
MM OE7*\28+D-E52K"4BES"K]2G<2BU20I<IO;U]PUARWSS&/*[2,2F06880.
MP#]G@-:M#T81FVD)3SIL?P1*?OP)?X0/^*.TOKC%HL4?*S G%;=4ZL5ZK*AA
M@B'?IACE_<MAOAJZPW5A$4+#KGF4??W,TZMCFD.%O>'B3U8HOA;>W!4NB-PF
MP3#?RQQXU H0:U;77]#V%B'+.8%&5.\D66/-)4YKAD3K&N&<@.@SUM#H TR@
M=@W.L/,H>G&6.\RUCZF9A2NDLN. S9,V6-GYM,'*/FUP75&P"\/5;&I.3\$2
M*H:)1X\W,P)V%I:*48\[C#&,51Y]^7Q?&1;@A:$-)3[U?,[N4!%KK52L'P\;
M$>M(L>!L!4KEQR1YN-2P\!@40Z,FKU'4*0BER+.DHJ,$^G8_Z/4TT=@W.H^"
MWB^KD7!9#)!BV0 WJDT"A:@;\KQ! F ]H +U3FO#'%[VD9(T(B4+ HBX)YR\
MRV;K,%!OL,YP2<R377;;,<UQD)^:.)#SB(&S&>Q8!18_4/T%X&&A^68XP;<8
M3-HAB%6(D,9F!L)J5:TVL+GKEY'$4874<T.MUVOPY?]>_7I]>7^H, ""&M=M
MC**Q@];%K7HH+ZP>-^J8O?-P$7[2J%6K1<H(N%(/Q_.5WBI0,?^ZII<4<6U;
MMF92^U .IJQM4_>@D>RPQ'R(-3)FZKP'"]S\<J,VD#F^M![OY9K#1Z BJL &
MS2^%<O29>EPY9@>W_ULIQBX[!MYX;%T7RF^2HO7F"1]GAML7&CI6<2;8Q@R8
M-:<879]?-0MJI1IHDA_G%VJY/I9B-)GBONO)*D/%'O<WDK,MSA$S8?G@%F=;
MQ+-1(J<L@1;82,+?D;232+)FL\BU<*92)8,>*AY.S!W/HI;AF^EDMX*J]:C!
M_+ -][ Y>EC#CNYS6,<>;P63SR7U@L&:YGC?\.3^., 08+\XY@F =Z]04_-A
M,!K\=#(@LO,(^,JR7XD\/1!/+Z+N%5UN./F<B0<?!N<*N<"J?06;]L@921<<
MW^%&9PS9^H!J]7_CEBS5E].6I\U1+LC8X)WA*61!8OBPB0P=S?(;[^/P73I%
M+JFT6W)YF%N#>39TE$M"EHU,HJ!SCJ)EB(J[@P/QZ!SKL+^-8<GN]-^.'HZB
MHP SSGG#+@DQYHO.\HCS'Q\Y_B^?&QYFJ$RV^IG(7HFU4)I=52\/K*"V2JSG
M!YT_3,'UZ)A(K(U7*\S];O3[0>K+K+Y*"K93HHY(?;P*5VZ\$430=@ANW0=]
MT@KZS,J$>8N\EW>-WFQ?[LK2:2HIUR/$C4,\KV6D)G963<+B\TZO-_+20UAK
MRLK9_>7E_\54%9F2\C!P/3J6SO3[OLL 36,C9;"6KA^[BZX,#.DHGAAY<O,/
M>'!3W9C:F_47U<3.!#ZXQKZN$[6%.U]10Z" '4CWY/*1S#^+6_\0([B''PF?
M',3.(SL<J2/<1PYBD8,_;<?4\8PNN2U-N#:N4Z/Z!/B<@/G'80=/@%*WIM\S
MN'0D>[[I&7@8J"<<APYY%.%!E*;L[!:>SSC68BD!B#M=X:-^,;#G'+@WQLY4
MSR0M2$P_Q-=C1EE1A@\Q.CL=>>(K"1O5G4_8J.X3-M;,B]0NDHK(V;_ #P;U
M!7]9X(UBU>:]+*#8E./!4H,EU!>T$Y&A)[CK.\*-51Q1.H8A/\$3A$UJ.!J%
ME[J.P -N+:^+Y_GAB8BR V=9#1ITHHM3*JK'\>:DE'DF_7?J!WF.AV!:E/H!
M7CN(,\8(9%B (BQ?A$7]BP=TW"(Y]? +@$0JK0+?'D8/)LEE![^8.B:%?&DV
M[WYQZ-=#;/MLXM@I+/5BP.A![\*M'4-:-Y[/W=A6 >]A$Z0X@OE8/.CIW!:F
M 9;+E3&2Z";#PH:%TJ/#_L:NZ/BR![(\\,]V7#P@66 4UL(34YVPAM3ZCV]I
ML?Y_8YDM]'3,GC%M6I:1P?AXT*'K:]W1]^.9BI9L;(WI23^B/W$\,!A.C6&1
M;FU??Q(># U /,:%L3H)VU#*DU2&E(A.!NS[3M]V<1C -D!&*GG6W&&_6#\P
M63T:I3SS6B[MQ+'E]([@F&@&[Z<9P*H?47@SO(UQ';MC2/+A6Q"4]!V#CCNG
M"?WHHZ&D JP@=HD'97:P 7/B^S4L. LF#(MQ%![N)L5T.;D*Q"@<<XQ+D$IR
M"CT*D"&E O:@]I@!=Z @(-HR9'&7!9+4I9[D$M'20<&QAKJQI1D2CI*?YIFQ
M[.T=+-U0*+EN]X-6OV00X\^2HAACQ&"T4H0-2X<).H-\KB]@L&,DS7!0-#TU
M&JH"K 0=T066[0W5G71/.'4)=@3H Y?.898GZ/*A0G-D^DL:C$F1<K=K^R8F
M]YET/CI)Z:CZ"3O;ZS+@W0=E2CIF3!]%BF)8<(@F 1/PHNDA&8Z&NC&T*/E<
M<#J[+H!]A>S\#-@9.X3([N<=:C&.A8[ 4T%/<6(_(Q!OWXE8[2@&BK)NJ^='
MP;6=1\&U/0J>SHMQ>O9-PRL\B">4TI",/#BN,^/"\.UT"+N_QK9NOYTFORS.
MG1H=&9V^3S_.R'-FEYU-F<K9Z53]E.G9'/@6]W6#SDHAW&_[+NAIN$;\0-R-
M>(.Y7<)[/;16[N&KDTUY8DO%Z)I7K2\W__QP?GGS>'F_P&[;<>J;;5.:C(TH
MS>0=L@6W7A)#NN>W2!:@1.W#4H\=-1.2=1'XHO]W+?V_2_3_TAO[O)L&;T37
M10[)6@>Q9YOXR/.>E82J#C-%=W5A2F^Y,!@(6?>:;#'QU..,,/22^^Z!1:E7
M5MS*?:2F,N16.>)96+X8ITOJ^]8IM7CX:=I %]N@F7!4/IQ6:PVE6JRG0(CY
M&[7L'I4KQW6E47T+*J^I+?&<-F?:9;.>.3_OS':^E[IS@5=N^L3>HNWOROIY
M&"DS+,WN"7: ";-K.LHW?0VWDK(XJ-4J2K%82>>A<IB[0;DZT*T^@10SKEI7
MDY8H4+S;$E,\5BJ-5%=^-RBGEFI*79T )AD0F37;&I(92WB[*"WU4E&I54I[
M:5E86HHEI:RF2K@,&YC(M.RHF-34AG(\&7C:B\E,,2E7E&JZ^N5MC<K>V]V:
MB65,IY(^;7/7T-CEW4/VM,%$"&PU%5H^*I>W7'^F2['B4:6QN7IS9:2Q.Y)1
M.FK4]I*QD&344E4E63<2NF'ZF-BW"\*P-Q.+FXD=C-E$9F*79&-O*!8W%.MV
M/;/>Z8>R1.]EB@.[$!XWS$U-$)V8Q;;EAB9E@$ZMLGX]8SQDI%'R[-,\MSS-
M<]'8S90TM!6#7MN0U+B=V:8;FMGXX?3GC*0M9IEE]WFXFT.\]>?A;BWQSKO<
M>II(U]VL-.;Y45( >MV/6[XYLY_8IDULC2WJ\678ZD<M50UKV+]MU>3HW_AW
MWC$HAZ'OV'@ ^3[Y/TI+KQXKE?J$5=HG_Z=*Y7*]JM14=4_EF:-=F=2EB<A?
M2N/^^2T PA1-N,JX6YKIN\;3/.KO_>/ :TA%*M65TOIVU+>=>$6E5MX3;TFM
MG^HFQ.KZ9T'XM2KD>C:&^L8><-,;A'IGXL"7K5S^:DTII[NIO4.R4ZDJU?H$
M8-H3;SZMG6KAV&8"GRD!K:@/;]JJ:9$ VNC6VAIZ0T_CJO6\,>2ZJE*9S$EY
M)4#W/O*RZ\NDUI1B>0N7*6,ZN+I(I#]KB#!UM7L7:%ML6;C7N&F)\I3.'9LO
MRUNV3I5J8N^/S5^GC.G<2=R;09V;(3!\;9C8/=F2!YGA ?,.'T8']XIY:48L
M;)^H;]D*58I*L;A()DO:R_3J46]S*=XWWB:>2IM-+<6<)'OIJ$HG.DPTB4M1
M%0;O6%C4Z#ZFVW[;%"EO<Z[M?8O!5'ICMK3B#B[6E#YUV[%8&<.KZDR\F@*9
M1Q'KAIQ[]7I;_+.1>,)]$$^XCW1U5$V1S[T6>(B.X/G+YW284>+I.X:EX3',
M\$6I\C/#$]+IGCX>A\L&@@=G+&#GK6>![;T-6YZ)$YSP0*>*A ^A8QB"?"0<
MTBN;\_)\%SR9&]XX+5K-.H[=8\%N&UX?QK>/V##K*9^;>/2B,R_-.W,%OX;5
M-,P!TQWXW&+M03X'MOS%Z\9..F:ZZ.%XN>;@,=C<Q&.0PT-=W4P?!+W <13U
M$W;;IQE]Q,<_"#HJY(3]P4T?O][YTRKJ^],JUG]8Q&W4%_ R..MI0RL!)R;"
M'OP>O&*PKPE<4TW@*.A\VY/5U]V9:4U%</MA9+>^:E_QN=7+NZ_XW/0RL'W%
M9^;J[O85G_N*SWW%YXH'UZQ<PT:[$9KMTD&GX^&<%"I>-KS JE17RI.2MI/U
M56LD<DFI-B:*07:2R.LN8EM7J6 64P;7<8KT=%7Y\.WN%*B+/Z*0R"Z4!*A*
M75W;N2A;3CRUKA1+^RJX94WSQA6CI!I8>[^,G;1>N9]81B>6,3,>9$RY@H)<
MN+NK@]4U[3X>L;X3NDY5BHVJ4FJLK3/OEM.O5"\JU4IU3[VEJ%<NIEHP^V:F
M-D-NPU3MA?Y":??<!E!HU9I2K:=:4+Q#(EFJE!6UM&\"L*1"*Z=J"M8;_-@[
M#/N)97UBV;7E9'U=89J&]:2P)V$)AYMDA;G>,RS#]62:Z4[H/555%77?LVI9
MZI7*RG%C;W.7H]Y!NE'BGP\S&:I8@^LPC_)"]Z&\>U[$<1U<B+U +FL,BJ#.
M)O:V]]2;4YVEVX1O=76VWW_8-=2]M1/+F%&7&_^4-(:U%!UN..P9*ZTP$8!K
M?_F&:V#]5<$1)L?#X[#C!9AL+$>#7UU#I_(2V]H)S5A3:NENS>Z050':[9M3
M+FV1-],@9\C52$7'H1-2V3U?9*(USUYLLT2W/3K:[S/L#(=L[<2R:XV#Y&#3
MY&U;&D)F8@,*M\L=,),[H<I+BEK>IP+OS6#F=<$Z@@2Q"H&]$M@K@;T2>$LE
MD&[WL? %Z;7+H>*@(^D4LYFU1$S\T$Q?AU^\KLCG>,\&Q?:WU"=PN6EHV*-&
M!S_=$Z8I-,_G)CZD#PIP0"VXPO9?Y*QC7QO/IA9;,4<>GX0?7?IX([=8&^ZP
M!&@K^*)YWVI>L#M06SVN"9_4JJOD<RU+.Z+]1[PS'+[KV=KW0IN[%!7H80,=
M&FN:S;9DGN0$!:>E50(%94.BD)3YW+N,N#PQXCEV<Z/!YW/!Z-^'W)5)AIT_
M/I3/30L0,<-EEF^:V>[%EEIP[=/9Z7W I2#*4]@TUI0IF,IR[P_\$'Q-HHSD
M<PEO7[1I7[FH_DRO*)>K/ROX_#[VGX/G#I2@<Q]<%6@<E_>BYH6&E<]AXX*1
M7G[ 07"IW^\X]@2G &O]U"A6&<S<Q+_#V"/<8/M.'&F!U/ G1PB:UXOA==FU
M[?2[]L/ /6)3.WAM*;\]!#HFGYM#R:R1]?*Y1;3=?&RHBY -U:+D0K4TE0E!
MZR=Q(9O"A'BE9_307@+G:6!-.5P<CN]H$]A(]N7SL+7G9\/BEF8 T5L6D+87
M[$!.:]"WRCO#>;QMK]9AUS[0338L\ $Z6X<C;5HGU:&=?->BW/>ZGB,.&S(8
MJ-W7U-Q2:@WX%P8*RPO\:W<ZKO!8>T!#B?5$'3:IS>?&6[SNCOT]YVX7E*$&
M/Y@ I *X!>@I^^#">[\+C[=-6$*A^0Z &'A\WY9H)CWEV'2I7^\8/^$(+H0F
M>FW@./DI:B8<J?QWSO%ZV%D>..@G]:C,VH&UQ,M_*AVIX0= @KB:/&*/P"PA
M1P-;=-"5()\CXM,^'Q#KX:,(=[*^#Q.0UR]CB]/7H>ML<3IG-][&OO%NU'BW
ML6^\NV:N),4Q-.Y??$.'7\6&6'74.>=H.ZT! ST":H1W.H;3PW &*)\..(:R
M!3A-LQ--\RF8)B@QN$L'%6B@PFN#,_,B-=G]+[S7/[F(O)KP#F;9+VCKHXC*
M$''&=%C+T@:>^,5Q__+M$QFQ)=?6XQT.MH#W>#ONN:%[Z\)X?4 )$C=$.FXT
M *RPMN\- SHC[@P\/AD0]+FASW[T43Z'\YZD$0B-:X\$D9@!%-<H?("$[]L>
MS %OZ?B>#Q,E,"Z>#(W!+Y;+M75W2]_(+L'I'1PTWFNN@EJJ":RO<X\C<@M8
M9*(#VYJ'D!@,3FC2%[<W\W7=6WEHY[[C)+1[>#N"O/,JO!_E[\!C,&S??8LM
M^(0!K'Y@O#RM8F9WPY7>G=8^4^(@)A=]]>VGF2]*.\OP)U5I-(JL $Z*<EPM
MLBG)@:ES0#*AUKC822*ZXNN^63+TKJ]MZWN6#DE]65X[H691?;O&Q5RK;EU$
MLM]P(.E+?E'*/6#?*5+_YNRW')'?D=$RK57>P[)3-/=\SL[%>]N^9@DO2PDO
M3Y7PO5W?#;N^AK*4J4(^N^=NAA7Z'CG,A1SJI%?4TAXY[)%#FLCA?E;JV!Y"
MO'5XH*0&X8%28Q\>V,.(M&'$;(F?W8PSPVI^CR?F4C+%^K%4,FKE>(\I]I@B
M34SQL$"ZXQY>O*WD5XM5E/OJ/D*QAQ:I0XN%!'^/,K8=950J%+6HU.M[A+%'
M&*GN=ZRA"]D>>:Q7&Y0(>)2FZH(][L@D[IA_!8(DQ'KEY\G5F))3M8Y=DK2:
M=[W>2#AULN'1DPNGP:T9'<2&EAG$$C\$=%+F?YKHN?!6"Y4>VL@&ZR0IL\5'
M5IHVM&3%ME$-#)KZ?WPWR)N/5ZA/:U20S[UUIP(VTJA N)[1"XO2WZMGP32B
M18-+*O#' ;]%>X)I@YM2\)_/#4<=5!#(ZD(C+*H(5M+EIJ!E"I<9GH3/C5I8
M@'0YAF<[@Z48@$KJ7N& +%<X?I9TB\SWL(RC)[@+7[EPQV"DE(.J.+!6!NM/
M8.9/MJV_&*;)0(YLJOGEKBL\>*5<-S<D]R@@P))"D#[#>H95[%%E(5PW5L1'
M52B.9PD''F?!(*D:$>481A9MF6!%851"DZ0"J/;$,JC61#=<#8 9\+A\&U7X
M/ C+@.'?V)YP(X$-JU7D=1[_@3KC&;A!/A0?Y @O9$\7]0M=B5.4K^:F:;]0
M+4Q8RHE/TT4'^ U'"X^4M,HTC\Q3?'B\+SZ,B@^/]\6'ZVHK<&Y;(#M$SG,0
M+A+5/T4;M((WVE]@(ZH09;4?(^79M4V=<?2#P@EJX01?@@EZ70.TL>U88)_R
M.>ZQQL=BD?&CWA&[O'@\8H\VF"L-$8ELU#/R)(7U3:JPUE$)-NKU0J58+Y2+
ME1(!(-WNH3'5Z%K0MJC,2T6U4&X<%XJ-6H4N(KUK$86YB97L=.D1^+:"JOQ[
M?=#!BM224;N@:!3P$;A['3",I @M'\O-%::6ZZ"!&^5,J\!6APULGV$UIF]1
MV3M8&NI\H!E]L#P*+)TC^B8?A.9F.'%)*+G*;;!-S]PPZ1%(TG*1Z1R[PV -
M9? $7*&"$5(H:@GQ#0P8&(T'CZ.1 E; 1:S5BH5:HUJ.C-;DS1+W1NL6K3 \
M 5>XII8*]8I:'>>?8# X;1JZ)82^34OZNMY_G)0@209$0OD<K&,HE29U&@#J
M:P@)14!"H!4(:*COOYU*F&,[1P;)_!$ :FR"DFT*G9TVV[;O!57)FZ54@;LY
M^],PL8^.AP70%P 17T" I4NCL"?3;H,TM V[/P+:I;.#]<D=6_-Q(8&S 1:C
M#XTPQ*>B9))*%QNM^%A^W1,> &8=[R=!01%R;/^I&\@D0,YGX0R4D80?8AJ[
MUQ,. NXA7,WGT#=U#.%QAWJI.+Q/@\LX3'Q5H#X#O3 0$2@A8VBL@;[4TF^
M:C0P4HBRX^+3&I$:HES'1G#-X,O_"?ES4^1)5H.2[_N+(YY. O?WP/%_ ,P%
M]]-H'VZ(M 6%K21M'<-Q/; ]!<T$KX;]UOQ=_17^*<%B=XTV^M>,]Q$<8,>$
M@>PJ^>WHX8A]OFA**P>PEUQ!&7\0CFWH!4=T''##T#GGF@^2_>6/KQ?H*G+=
M-Z40]4'RN.< >@%;;) KJ9:H?X-TY@!:"2?3K!$C(WK:J&TT&=<8)TO?-@?
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MH06 )%/A GL5+8SB!*_+/1P][C#V7?GVN$O:P2Z]< G&+7"O$'>5+;D[[0X
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M.\%NX)0V3*%&C"&>,6N,SJ-KM,$CDW;/MT#+8=)?QS?!4N-FJ>N#]M0,(;W
MGA!>&*;%_4^ /SZ,"..'Z$KJ0'M*N'VAP*,7U$7Z8F1@$LB 2)JXP885,I8#
M5H+%7B6!E$0+ ?6)$F/C#V >4'8!(+00 AJZK<$KP6/S8?X#K)4(ED9"8P#4
MP'AHX 9AWC"6>LB*G>%)4TAF&##@ 5<:V2'$&E^[*-D.R!"AKQ/:['4 - 0,
MVN.Z" /8@%Y/XK/X;T0A?3QY#=4:'A7JA?5$<&O7Z <PBAS(T1(7"7R I ;&
M<)(+62+R WVT :Z[RSO"&TS# @$H'M:E1!_, Q[RN='W8@RI+P-V:WE?-,V
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MB[#[FA*-E^*EE1X<0@=542=;M\VSW3C7MM664Z]<76JG-@OV:NG]VJE)L9&
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MUK,J:/CSZ]GMQ;_)Z_SZ>'T%O_Q_4$L! A0#%     @ VCFE4.E.D5Q" P
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M,3$Y+3)?.&LN:'1M4$L! A0#%     @ VCFE4.1SUAD;1   E;X" !8
M         ( !X2<  '1M,C Q-C$Q.60R7V5X.3DM,2YH=&U02P4&      4
,!0!) 0  ,&P

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
